FDA expands marstacimab approval to children and patients with inhibitors, backed by new BASIS trial data.
News|Articles|May 11, 2026
4 Hematology Headlines You Missed in April 2026
Author(s)Alex Hillenbrand
Fact checked by: Victoria Johnson
Catch up on the hematology news and data you missed from April 2026.
Advertisement
Advertisement
April 2026 brought major developments in hematology, particularly in
Related to this article
Stay updated with the latest healthcare breakthroughs, including Bayer's finerenone expanding to type 1 diabetes-associated CKD.
Approval is based on 36-week data from BRAVE-AA-PEDS, in which 42% of patients on the 4 mg dose achieved a SALT score of 20 or less, compared with 5% on placebo.
The FDA approved once-daily oral zilurgisertib for FOP in patients aged 12 years and older after the phase 2 PROGRESS trial showed reduced new heterotopic ossification vs placebo.
Approval covers patients aged ≥2 years with frequently relapsing or steroid dependent disease in complete remission.
As the FDA weighs its first psychedelic approval, Sarah Norman, MPP, says training, credentialing, and reimbursement are lagging while patients are already asking.
Pranav Garimella discusses what a potential USPSTF kidney screening recommendation could mean for high-risk adults and primary care.
Andrea Murina, MD, weighs whether she would recommend medicine to her own children amid AI, physician burnout, and evolving residency training standards.
Advertisement
Advertisement